Good day ladies and gentlemen, and welcome to MDxHealth Half Year Release of Results and Business Update Conference Call. As a reminder, this conference call is being recorded. Before we begin, I would like to remind everyone that the Company will make forward-looking statements during today’s call. Whether in prepared remarks or during the Q&A session, these forward-looking statements are subject to inherent risks and uncertainties. These risks and uncertainties are detailed in the Company’s most recent annual report. MDxHealth expressly disclaims any obligation to update any such forward-looking statements to reflect any change in its expectations with regard thereto or any changes in events, conditions or circumstances on which any such statement is based unless required by law or regulation. And now, at this time, I’d like to turn the conference over to Mr. Michael McGarrity, Chief Executive Officer of MDxHealth. You may begin your conference, and please go ahead sir.

Thanks, Cody. And thank you all for joining us for our 2021 midyear release of results for MDxHealth. With me today is Ron Kalfus, Chief Financial Officer. We are encouraged by our expected progress in the first half of 2021. Our results reflect the key fundamentals of our business are now in place and will begin to drive sustained growth for MDxHealth. Our confidence is based on the following actual results and additional leading indicators. Volumes for our ConfirmMDx test increased for the third consecutive quarter, up 4% sequentially in Q2 over Q1, compounding on the 6% Q1 growth over the Q4 of last year. For SelectMDx test, volume increased an even greater 16% sequentially over Q1, while year-over-year growth for Q2 was 82%. Also notable, we received a draft coverage decision on our SelectMDx test for Medicare. And while we cannot be certain of the timing of a final coverage decision, we believe this is a clear indicator and validation that our SelectMDx test will be afforded coverage for a Medicare patient population on a national basis. Our compelling clinical data, broadening market adoption, healthcare economic value to payers and providers and our inclusion in the NCCN guidelines supports this expectation. Based on these positively trending results, I believe it is important to characterize what we are seeing in the market with regard to the pandemic dynamics and its influence on our volume trends. First, from a patient flow perspective, we see that there’s likely a backlog of patients that deferred physician visits will be coming back into the healthcare system as the pandemic lifts. These patients have put off important PSA screenings for prostate cancer, estimated to be down 48% in 2020 and associated biopsies based on PSA and risk factors. While we are still in the early…

Thank you, Mike. The pandemic continues to impact sales rep access and the return to normal patient flow for not only MDxHealth, but the healthcare industry as a whole. While various companies may be viewed as comparable to MDxHealth, it should be noted that each disease state in cancer diagnostics has the unique profile related to the impact from the pandemic and its associated recovery. While we have seen signs of recovery evidenced by the sequential increases in volume and revenue for both of our products, we may continue to experience some fluctuations with expansion and contraction by geographic regions, particularly with the emergence of the COVID Delta variant. Moving on to our results, total revenue for the first half of 2021 was $10.7 million, compared to total revenue of $9.9 million for the first half of 2020. Revenue from ConfirmMDx and SelectMDx for the first half of 2021 amounted to $10.5 million, an increase of 9% as compared to $9.6 million a year earlier. Q2 2021 services revenue was up 43% from Q2 2020. Gross profit on products and services for the first half of 2021 was $5.2 million, as compared to $4.7 million for the first half of 2020. Gross margins on products and services were 48.6% for the first half of 2021, as compared to 47.4% for the same period in 2020, representing a gross margin improvement of 120 basis points. Operating expenses in the first half of 2021 were $17.7 million, consistent with the same period last year. Excluding non-cash expenses such as depreciation, amortization and stock-based compensation, operating expenses for the first half of 2021 were $15.7 million, an increase of $0.3 million, or 2%, over the first half of 2020. Finally, following a successful equity raise of €25 million or approximately $30 million by U.S. and European investors, including existing shareholders, we ended the half year with $31.3 million in cash and cash equivalents. Our cash burn remained comparable to prior year at $13.1 million for the first half. This concludes my brief overview of the results. I will now turn the call back to Mike.

Thanks, Ron. I hope it is clear that even amidst the challenges presented by this environment, Ron and I and our entire team across all of our operating functions remain committed to and believe in our focus on execution and our clear path to build value. We expect the fundamental drivers of our business will become clear and obvious, as we go forward. And while we will not be providing specific guidance for the remainder of 2021, I would like to emphasize our expectations and what we will advance and deliver going forward. First, as urology group practices in general and our customer base specifically move towards standardization of menu and laboratory service providers, as well as adoption of clinical diagnostic pathways, we expect to leverage this trend into sustainable growth for MDxHealth. Second, the recent determination by MolDx, that our SelectMDx test meets the necessary conditions to qualify for coverage for Medicare patients and its draft coverage LCD will not only catalyze our focus efforts to expand coverage among commercial and private payers, but will most importantly, together with our inclusion in the gold standard NCCN guidelines, support our efforts to accelerate adoption by the urology community. Third, as I noted previously, we have refocused our R&D resources, from product support and advancement of our existing menu to now investing into menu expansion that will supplement and contribute to our future growth. Our efforts here will expand our menu into active surveillance, where we believe we can deliver clinically actionable results for both selection and monitoring of patients for active surveillance. All of these initiatives are designed to put MDxHealth in the position to be the only company in the prostate cancer diagnostic space that can take a patient from an elevated PSA all the way through the diagnostic…

Thank you. [Operator Instructions] We’ll take our first question from Lenny Van Steenhuyse from KBC Securities. Please go ahead.

Hi. Good evening, gentlemen. I hope, you can hear me well. Two questions from my side. So, you mentioned indeed a bit of a choppy patient flow, a bit of an elastic patient flow now as the pandemic continues to linger. Do you observe any changing behavior with urologists to adapt to this changing long-term, let’s say normal as the patient flow continues to be choppy? And does [Technical Difficulty] your approach of existing and novel customers? And then, I’ll have a follow-up to that. Thank you.

Yes, Lenny. Yes, we do likely see, as I commented that this patient flow that has been -- or backlog that has been building, will come back through the system. And we have clear visibility to the fact that -- and I run the risk of overusing the pathway term. But I think it’s important because, previously, I think, prior to my joining the Company, there was always a question about, is this a Confirm company or a Select company? And hopefully, our message is very, very clear that we have a prostate cancer menu. And when applied in diagnostic pathway is just very, very clear and straightforward adoption profile. So, as these patients come back through, I think that will become evident. And secondly, we’ve made the conscious decision, obviously, to continue to invest in Select as part of that pathway as opposed to waiting until we had coverage. And we think that as well will pay dividends. When you look at the growth rate for our Select in combination with the progress with Confirm on the pathway that we have a lot of leverage in our P&L and associated gross margin, based on our confidence that we will be able to run coverage over our Select test. So, that investment will, I think our patients there in focus will pay off and then our expansion into active surveillance as well puts us in a unique space. So, we are very, very positive, we probably just need a little bit more clarity as to the release of that patient flow.

Thanks for that. And perhaps zooming into the UTI side, I was wondering if you could elaborate a bit on, let’s say, the process behind the addition of the tests, and how the financial dynamics of that test compared to Confirm and Select in terms of pricing and margin?

Sure, Lenny. I commented briefly, but I think it is important to note that we’ve spoken to this, right, that we are -- we believe we’re building a clear channel in urology and a unique channel in urology where -- that’s our focus. And we, based on that, I think, we’re starting to become a little more obvious in that regard. So, we get opportunities that come our way for potential partnerships or distribution based on our access to this channel. I think it’s very important to note that this is not like our tactics dictating our strategy and we’re going to try this. This is, we believe the exact opposite, right? We believe this fits with our strategy and our process within our sales organization. And I do want to emphasize the work that we did to confirm all of that, and that the dynamics from an economics perspective are actually pretty clear and derisked. And again, I use the term well-characterized from a pricing perspective [Technical Difficulty] between our Select and Confirm with potentially a $1,500 type list price and coverage in the high hundreds. And then, we have good visibility to -- I made the comment that as we recognize revenue in this opportunity, it will be accretive to our P&L and gross margin. So, obviously, more detail to come. We’d like to get a quarter or two of experience and we want to be very-focused in our launch, both from a quality and execution perspective, because in my experience, it would be reasonable to have -- somewhere here or there, we’re very confident that we’ve done the work and we’ll look forward to giving you a better visibility as we come into next year.

We’ll take our next question from Kevin DeGeeter with Oppenheimer.

Hi. This is Susan calling in for Kevin. Just a few questions. I believe the comment period for the new LCD ended in July, and I was just wondering if you guys have any thoughts or any comments that you would call out.

Yes. Susan, I probably have to lean on my difficulty and projecting the timing. I would just say that our confidence is very, very high and the data, the clinical utility, I think the inclusion in the NCCN guidelines is quite compelling. And we expect the comment period to reflect that. So, we are through that. And I think from my perspective, it’s like the FDA and Medicare, we just can’t and don’t want to guide to a specific timing. But we know over the coming months we’re very, very confident, next between the fall and the spring that we will be issued final coverage decision. And as I commented previously, we think that that provides a significant tailwind for the Company. And we’ll approve out our focus on continuing to drive Select while we were not getting coverage.

Okay. Thank you. And just actually another question on the other LCD, L37733. There was an update to that LCD, I think at receiving expanded coverage. I was wondering how that might impact Select and if at all.

Yes. We don’t view or have any particular comment on that. We believe that, our Select reimbursement and clinical utility package stands on its own.

Okay. And one last question. I wanted to know what the impact of Delta is on the Company’s commercial organization, specifically in-person sales, travel and things like that.

Yes. I mean, it’s clearly -- it had an impact as it has on all sales organizations, particularly in the diagnostics space. So, I don’t want to quantify it to some specific impact. I would just say that the biggest impact is probably on access. Our team is fully-engaged and has been productive. But access will clearly open up, or we anticipate that. But I think all the companies in our space are reporting 50% or so estimated, management estimates, those are mine. But that’s probably right from an access perspective, so. But, we’ve been, as I said, fully engaged.

Great. Those are all the questions from us. Thank you.

Thanks Susan. Cody?

Cody, can we move to the next question?

Cody? Please bear with us. There might be some technical issues on the backend.

I do apologize for the inconvenience. We will now take our next question from Laura Roba from Degroof Petercam. Please go ahead.

Yes. Many thanks for the clear presentation. Three questions on my side. What does your current development pipeline mean in terms of R&D expenses? Could you provide some guidance on that? Second question, how do you balance the focus between the commercial relevance of your existing products and the development of the new solutions? And finally, when do you expect to launch the UTI? Thanks.

Thanks, Laura. So, in order, from an R&D, OpEx perspective, our focus on expansion of our menu and active surveillance will drive some investment in R&D. However, we feel like it’s largely absorbed by the growth in our business. And it’s important to note, this is not a significant expansion of fixed expenses related to headcount. It is more associated with clinical studies and samples that you would find to be common in a development project like this. So, we have -- we are very-focused on, and I think it’s coming through our numbers and will continue to on operating discipline with regard to operating expense and our cash management. That will continue. And so, that’s where we view the R&D. And your second question with focus. Yeas, we have paid significant diligence in respect to that process, right, because I’ve emphasized focus on execution. It’s a really important point to note that we think this is not contradictory to that. But it’s very, very consistent with that. And it’s based on the fact that our target customer, and I will say -- when I say target customer, I don’t mean, all of urologists, I mean, our focus, qualified customer for Select and Confirm and with the -- or the introduction of our UTI test is very consistent and complementary. So, we do not anticipate -- and we’ve pressure tested this a number of different ways that it will be dilutive to our focus. We believe it will be accretive from the perspective of quality of our sales team, and standardization of rep, company and laboratory in neurology space. And that’s why I point to that $4.5 billion total addressable market. Yes, that’s large. And we’re not selling that as anything other than we are -- we believe that we are the only company in the space that serves that market, from front to back. And then your final comment, we’re using market introduction. Mainly because of my experience, we want to introduce this product in a highly-focused and quality way with our customer base. And that’s what we’ll be doing here over the next quarter or two. And I would expect that we would be speaking to the full launch strategy, how it folds into our view going forward for the business. And obviously, as we build our internal models on value-creation and work with you and the market, we’re confident that it will provide good growth. We just don’t want to get ahead of that. But, we’re very confident in this.

Thank you. And that does conclude today’s question-and-answer session as well as today’s conference. We do thank you all for your participation. And you may now disconnect.